Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par pays : Macedonia, The Former Yugoslav Republic of
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study
This double-blind, placebo-controlled, dose-finding study is designed to identify the lowest AGI-1067 dose that improves glycemic control as measured by HbA1c and fasting glucose in subjec...
Pays
Bosnia and Herzegovina
,
Former Serbia and Montenegro
,
Georgia
,
India
,
Macedonia, the former Yugoslav Republic of
,
South Africa
,
Ukraine
,
United States
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attack...
Pays
Czech Republic
,
Germany
,
Hungary
,
Israel
,
Italy
,
Macedonia, the former Yugoslav Republic of
,
Poland
,
Romania
,
Slovakia
Organes
Aucun
Spécialités
Aucune
Essai ouvert aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients
The aim of this study is to obtain data from hospitalized Community Acquired Pneumonia (CAP) patients on the disease including disease severity, clinical signs and symptoms and measures us...
Pays
Croatia
,
France
,
Hungary
,
Jordan
,
Kazakhstan
,
Lebanon
,
Macedonia, the former Yugoslav Republic of
,
Moldova, Republic of
,
Romania
,
Russian Federation
,
Ukraine
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this research study is to compare the efficacy of adding inhaled preprandial insulin to glimepiride compared to adding rosig...
Pays
Australia
,
Croatia
,
India
,
Macedonia, the former Yugoslav Republic of
,
Philippines
,
Russian Federation
,
Turkey
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
nct
MAJ Il y a 4 ans
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
This study is being conducted to confirm the efficacy, safety, and immunogenicity of recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of acute angi...
Pays
Bulgaria
,
Canada
,
Hungary
,
Israel
,
Italy
,
Macedonia, the former Yugoslav Republic of
,
Poland
,
Romania
,
Serbia
,
South Africa
,
United States
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Professor
MAJ Il y a 4 ans
A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia
This study consists of a 4 week run-in period with a Ca based phosphate binder and 12 weeks treatment period by MCI-196 or placebo, (both on Ca based phosphate binder). During the treatmen...
Pays
Czech Republic
,
France
,
Germany
,
Italy
,
Macedonia, the former Yugoslav Republic of
,
Poland
,
Serbia
,
South Africa
,
Spain
,
United Kingdom
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Professor
MAJ Il y a 4 ans
A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia
This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised,...
Pays
Hungary
,
Italy
,
Macedonia, the former Yugoslav Republic of
,
Malaysia
,
Poland
,
Russian Federation
,
Serbia
,
Ukraine
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations